



# Genetic engineering in organoids

Isaree Teriyapirom<sup>1</sup> · Andreia S. Batista-Rocha<sup>1</sup> · Bon-Kyoung Koo<sup>1</sup>

Received: 1 May 2020 / Revised: 17 November 2020 / Accepted: 14 December 2020 / Published online: 18 January 2021  
© The Author(s) 2021

## Abstract

Three-dimensional organoids have been widely used for developmental and disease modeling. Organoids are derived from both adult and pluripotent stem cells. Various types are available for mimicking almost all major organs and tissues in the mouse and human. While culture protocols for stepwise differentiation and long-term expansion are well established, methods for genetic manipulation in organoids still need further standardization. In this review, we summarized different methods for organoid genetics and provide the pros and cons of each method for designing an optimal strategy.

**Keywords** 3D Organoids · Organoid Genetics · Pluripotent Stem Cells · Adult Stem Cells · Genetic Engineering · CRISPR/Cas9 · Disease Modeling

## Introduction

Organoids are three-dimensional (3D) *in vitro* cultures derived from stem or progenitor cells, which can recapitulate the variety of cell types, architectural organization and function of their *in vivo* tissue counterparts [17, 64]. The first attempt of generating organs *in vitro* began in 1907 when Wilson demonstrated that dissociated sponge cells could reaggregate and self-organize to reform the whole organism [117]. Current attempts to generate organ-specific models grew from the work of Sasai and colleagues, who showed that three dimensional (3D) cerebral cortical tissue could be generated *in vitro* from pluripotent stem cells [26], as well as from the work of Clevers and colleagues, who generated gut organoids from adult intestinal stem cells [95]. These studies led to the classification of organoids into two main categories: pluripotent stem cell (PSC)-derived organoids and adult stem cell (AdSC)-derived organoids.

As there are already multiple reviews comparing these two categories [17, 43, 64], this chapter will provide only a short summary of the major distinguishing factors between PSC-

and AdSC-derived organoids. In principle, PSC-derived organoids are grown from either embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), which we will collectively refer to as PSCs. These cells are first cultured in suspension in a defined medium to promote cell aggregation and directed differentiation [43]. Cell clusters are then embedded in a matrix that provides structural support, allowing the cells to organize into structures resembling the endogenous tissue. PSC-derived organoids can contain different cell types originating from the different germ layers (ectoderm, mesoderm, and endoderm). Since the first 3D cultures of the cerebral cortex [26], organoid differentiation protocols have been developed for generating models of various other tissues, based on the presence of specific signaling factors in the medium. Established murine PSC-derived organoids now include models of the optic cup [27], pituitary gland [105], inner ear [59], and thyroid gland [4, 63]. Human PSC-derived organoids include models of the brain [65], kidney [77, 106], small intestine [102], stomach [73], lung [25], liver [107], colon [79], and mammary gland [88].

AdSC-derived organoids, on the other hand, do not require directed differentiation, as they are grown from tissue-resident adult stem cells in a similar process to that used for the sponge cell reaggregation [117]. AdSCs are first extracted from the organ by tissue dissociation, then directed to form organoids in medium that supports their stem cell activity with an optimal growth factor combination. Examples of mouse AdSC-derived organoid cultures include the intestine [95], stomach [8, 104], liver [15, 41, 42, 45, 83], pancreas [15, 44], lung [67], endometrium [14], salivary gland [81], and taste bud [90].

✉ Isaree Teriyapirom  
isaree.teriyapirom@imba.oeaw.ac.at

✉ Bon-Kyoung Koo  
bonkyoung.koo@imba.oeaw.ac.at

<sup>1</sup> Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna Biocenter (VBC), Dr. Bohr-Gasse 3, 1030 Vienna, Austria

Human AdSC-derived organoids have also been developed for the intestine [51, 96], liver [15, 41, 42], pancreas [15], endometrium [14, 109], fallopian tube [55], and prostate [53]. While generating organoids from AdSCs requires less time than from PSCs, the number of different cell types that can be generated from AdSCs is limited, as AdSC-derived organoids often only contain epithelial cells [43]. For this reason, they are useful for studying epithelial tissue maintenance and regeneration but not suitable for studies involving the interaction between different cell types, e.g., immune-epithelial interaction.

Since their development, organoids quickly became a popular model by bridging the gap between *in vivo* animal models, which are time-consuming to generate and costly to maintain, and *in vitro* two-dimensional cell culture systems, which lack 3D tissue organization and often contain cancer-associated genetic alterations. 3D organoid systems have been used for studying organ development [65] and host-pathogen interactions [20, 87]. They can also be used for disease modeling and therapy development, e.g., by using cancer and diseased tissues as starting materials for organoid formation [10, 11, 34, 65, 66, 96, 110]. Despite all these achievements, the ability to generate, repair, or introduce specific genetic mutations was needed for modeling monogenic disease and cancer, as well as for genome-wide screening and establishing reporter organoids.

## Genetic engineering methods

There are currently multiple methods of genetic engineering that have been employed in organoids, opening a new field of research—organoid genetics. These methods enable specific modifications of the genomic DNA sequence. If the modifications are introduced in a coding sequence, they can lead to a specific change in the target protein, which can provide insight into the biological role of a specific residue or the protein itself. This process requires consideration of two major points: the genetic tools and the method of delivering them into the target cells.

### Methods for delivery

There are currently two common methods of introducing gene-editing components into organoids: viral (e.g., retro/lentiviral or adenoviral transduction) and non-viral using naked DNA transfer (Fig. 1). Each method has its advantages and disadvantages, which will be briefly discussed here and summarized in Table 1. Choosing the appropriate delivery system requires consideration of the properties of the target cells, the size of the DNA fragment, and the required duration of gene expression.

Retro- and lentiviral transfections utilize the viral machinery to induce stable integration of foreign genetic sequences whose expression can be consistently passed on to progenies [62]. However, retroviruses rely on the host cell cycle to integrate genetic information into the genome, thus cannot infect terminally differentiated, non-dividing cells. Furthermore, retrovirus infection requires high viral titer and can induce immune responses that may reduce the efficiency of genome integration [92, 101]. Lentiviruses have an adaptation that circumvents this limitation, and are thus commonly used for cells that are difficult to infect, such as immune cells or non-dividing cells [21]. However, with both retro- and lentiviruses, integration preferentially occurs in transcriptionally active sites, which can adversely affect the expression of host genes. Moreover, both viral vectors can only accommodate a maximum DNA insert of about 8 kb, which covers most cDNAs, but not all [21, 46].

The adenoviral method avoids permanent integration by remaining episomal after transfection and is effective in both dividing and non-dividing cells [101]. It is also easy to generate high virus titers for higher expression of the introduced transgene. However, due to the lack of genomic integration, the introduced gene can be lost over multiple rounds of host cell division [114, 115].

Lastly, non-viral naked DNA transfer generally involves one of two delivery approaches: electroporation or lipofection. Electroporation utilizes electrical pulses to transiently create openings in the cell membrane, allowing foreign DNA to enter the cell [32]. This method is usually efficient for many cell types and even in living organisms, and can also easily introduce large constructs into the cell. Nevertheless, electroporation requires a relatively expensive device and extensive pilot testing as the optimal parameters vary significantly for each device and cell type. Lipofection utilizes Lipofectamine or related lipid molecules that can form liposomes, encapsulating DNA and introducing it into the cell [97]. This method is relatively simple and usually efficient enough in many cells. However, the transgene expression is normally transient, and lipofection may affect cell survival.

### Tools for genetic engineering

After deciding on a method of genetic delivery, it is important to consider the method of genetic editing. As there are many reviews comparing the different tools for genetic engineering [19, 56, 57, 120], we will only present a short summary of important methods that have been used to genetically modify organoids: RNA interference (RNAi), CRISPR/Cas9, retro/lentiviruses, and transposons (Fig. 1 and Table 2).

The RNAi system utilizes the cell's own machinery to silence expression of specific genes. In this system, synthesized RNAi sequences, either short-hairpin RNAs (shRNAs) or short-interfering RNAs (siRNAs), form complementary pairs with the mRNAs of the target gene to promote degradation or

**Table 1** Pros and cons of different methods of delivery

	Viral			Non-Viral	
	Retrovirus	Lentivirus	Adenovirus	Electroporation	Lipofection
Pros	Stable integration	Stable integration Can infect non-dividing cells	Infect dividing and non-dividing cells (Transient integration) Easy to achieve high viral titer	Efficient for any cell types and living organisms Can introduce large constructs Low DNA requirement	Simple to use Efficient in many cell types
Cons	Cannot infect non-dividing cells Can induce immune response Transgene size limited to 8 kb Time-consuming for virus production Issues with biosafety and mutagenesis	Transgene size limited to 8 kb Time-consuming virus production Issues with biosafety and mutagenesis	Transgene can be lost over divisions Issues with biosafety and mutagenesis	Costly Require extensive optimization Potential cell damage/nonspecific transport to cells	Transient transgene expression May affect cell survival

translational silencing and thereby suppress the protein expression of the target mRNA. This method is effective in all mammalian somatic cells and no prior genetic manipulation is necessary [28, 39]. shRNAs can be delivered into cells with various vectors such as retro-/lentiviruses, adenoviruses, plasmids, and transposons. [120]. However, RNAi is only a knockdown system, has lower efficacy, and is prone to off-target effects.


A useful choice for stable gene expression is transposon-based systems, e.g., PiggyBac and Sleeping Beauty, which can stably introduce the gene of interest into the host genome for long-term expression. Both PiggyBac and Sleeping Beauty use the “cut-and-paste” mechanism to “cut” the genetic sequence flanked by a specific terminal inverted repeat from one locus and “paste” it into another [46]. However, this random insertion sometimes occurs in an active gene, which can lead to unexpected effects on the host cell.

Since 2012, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems have been widely adapted for sequence-specific editing in both prokaryotic and eukaryotic cells in vitro [16, 18, 35, 50, 71]. The system was first discovered in bacteria, giving them adaptive resistance to bacteriophage infections [9]. The CRISPR/Cas9 system was then further engineered with two components: Cas9 endonuclease and single-guide RNA (sgRNA or gRNA), where a spacer sequence binds to a complementary sequence of DNA (protospacer sequence) and guides Cas9 to a specific target. A DNA target containing both the protospacer sequence and the protospacer adjacent motif (PAM) forms a target for the Cas9; gRNA complex to introduce a double-strand break (DSB). The PAM sequence differs for the different Cas9 and Cas12a (Cpf1) endonucleases derived from different bacteria species, thus enabling a broad range of applications [18, 89, 121]. Following

cleavage by the Cas9 nuclease, the DSB can be repaired by either homology-directed repair (HDR), which requires a template for precise, high-fidelity repair or by non-homologous end joining (NHEJ), where the blunt ends are re-ligated together [13]. Repair by HDR following a supplied template allows researchers to introduce specific sequence changes into target genes [33]. However, this process is inefficient and requires the cell to be in S phase of the cell cycle for the repair to occur [47]. Template plasmid must also be cloned with homology arms specific to each gene, thus increasing the work effort. Alternatively, DNA repair can occur by nucleotide insertions or deletions introduced by NHEJ which generate frameshift mutations, leading to inactivation of the target gene. As NHEJ is often viewed as error-prone, it is not used for precise targeted mutation. However, recent work by Artegiani et al. [6] adapted the NHEJ for generation of fast knock-ins in various human organoids. This method removes the effort required for homology arm cloning as knock-in DNA is cloned into a self-cleaving plasmid containing a non-human sequence which is recognized by sgRNA. The authors could show more efficient knock-in generation as compared to HDR even with TP53 inhibition which was suggested to improve HDR efficiency in human pluripotent stem cells [6, 48].

Further advances in CRISPR/Cas9 development also target increasing efficiency of different Cas enzymes to detect a broader PAM sequence range [41, 42] or nearly remove the PAM sequence constraint completely [113]. Modification of the Cas9 endonuclease by fusing inactivated Cas9 nickase to cytidine deaminase to generate base editors [36, 40, 60]. This introduced new tools to generate precise base changes in organoids [37, 112].

Combining organoid technology with the various genetic editing techniques provides a new platform for organoid



**Fig. 1** Methods of generating organoids and genetic engineering with their possible applications. Organoids can be generated either from adult stem cells (AdSCs) or pluripotent stem cells (PSCs). AdSCs, extracted from the tissue of origin, can be cultured with the proper conditions to give rise to organoids that mimic the organ they derive from. PSC-derived organoids are grown from cell line of induced pluripotency or embryonic stem cells. Depicted on the left and right human figures are the types of organoids which have been generated with AdSCs or PSCs,

genetics and organoid-based disease modeling. The following chapter provides further details on the applications of gene editing with the CRISPR/Cas9 system in various AdSC- and PSC-derived organoids.

### Editing in adult stem cell-derived organoids

The establishment of AdSC-derived organoids depends on the proliferation and differentiation ability of the AdSCs. To

respectively. Organoids can be modified with different genetic engineering methods such as CRISPR/Cas, transposase, or RNAi. These tools could be delivered with a non-viral approach such as lipofection or electroporation, or with a viral approach utilizing retrovirus, lentivirus, or adenovirus. The genetically edited organoids can be further utilized for various applications/fields of study including biological developmental models and translational/precision medicine

establish organoids of this type, AdSCs are isolated from the resident tissue and cultured in a laminin-rich matrix with the required growth factors that mimic the niche environment required for maintenance of AdSCs and differentiation to the organoid structure. Because AdSCs are isolated directly from tissues, one method of obtaining a genetically engineered organoid line is to isolate AdSCs from a genetically engineered animal model with the desired genetic mutation. In 2012, Koo et al. showed that deletion of RNF43 and ZNRF3 from LGR5+ stem cells in the intestinal epithelial

**Table 2** Pros and cons of gene-editing techniques

	RNA interference (RNAi) system	Transposon-based system	CRISPR/Cas9
Pros	Effective in all mammalian somatic cells No prior genetic manipulation needed Multiplexing possible	Stable integration for long-term expression	Introduce specific modification to target sequence Multiplexing possible Ease of scalability
Cons	Knockdown system only Lower efficacy Prone to off-target effects	Random insertion can disrupt transcriptionally active genes Difficult to perform on large scale	Susceptible to immune reaction Possible off-target effects

compartment induces adenoma growth containing Paneth cells and undifferentiated LGR5+ cells. Organoids containing the double mutation could be derived from this adenoma: they mimicked the same effect as *in vivo* and could be used for drug testing [61]. However, generating a genetically mutant mouse line or acquiring patient-derived tissues with desired mutations to start organoid culture can be difficult, time-consuming, and costly [23]. Thus, it would be advantageous to be able to edit gene expression in organoids directly (Fig. 2a).


### Gastrointestinal tract organoids

In 2013, Schwank et al. utilized a transient CRISPR/Cas9 targeting system mediated by lipofection to demonstrate that CRISPR/Cas9 could be applied in organoids for genetic knock-out or mutation repair [98]. First, the authors induced a frameshift mutation in the *APC* gene of mouse and human organoids. As *APC* is a well-established tumor suppressor and negative regulator of WNT signaling, the targeted organoids displayed WNT signaling-independent growth. With the application of the tool established, the team then repaired mutations in the gene coding for cystic fibrosis transmembrane conductor receptor (CFTR) in colonic organoids derived from cystic fibrosis patients. The targeted organoids showed restored swelling in response to forskolin, indicating successful

repair of the disease-causing deletion mutation in the *CFTR* locus. The results show the potential usefulness of CRISPR/Cas9 editing in organoid research and in correcting monogenic disorders [98].

One focus of gene editing in organoids has been to model the effect of oncogenes in tumor evolution. Downregulation of tumor suppressor *Tgfb $\beta$ 2* expression in gastric organoids through retroviral delivery of *Tgfb $\beta$ 2* shRNA produced various gastric cancer subtypes [80]. To further understand the complex interaction of oncogenes in tumor initiation, mouse colon, stomach, and pancreatic organoids were grown from conditional *Apc* knockout mice and then manipulated to induce overexpression of mutant *Kras* or downregulation of *TP53* or *Smad4* expression using shRNA. While pancreatic and gastric organoids showed abnormal growth in response to either single or combinatorial mutations, colonic organoids required combinatorial mutations to initiate transformation [68]. The coupling of genetic manipulation and organoid modeling was thus able to confirm the multi-hit model postulated for various cancer types.

The multi-hit oncogenesis model was further explored by two independent studies that used CRISPR/Cas9 to introduce mutations into colonic organoids [24, 72]. Both studies targeted *APC*, *SMAD4*, *TP53*, and *KRAS*, with the study led by Matano et al. targeting *PI3KCA* as well. CRISPR/Cas9



**Fig. 2** Comparison of genetic engineering in AdSCs and PSCs. **a** With the AdSC-derived organoids, it is necessary to first establish the organoids from the tissue-resident stem cells and culturing them as unedited organoids, allowing them to stabilize under *in vitro* conditions. To edit these organoids, we must dissociate them to single-cell state in order to introduce the gene-editing tools efficiently. Single cells will then grow back to re-form organoids which can be maintained in culture or frozen

for long-term. **b** PSCs-derived organoids, on the other hand, can be genetically modified prior to the organoid formation. Gene-editing tools can be introduced to the PSCs directly; then, the PSCs could be differentiated to form genetically modified organoids. After the organoid is formed, it cannot be dissociated again without losing its structural integrity and function. This figure represents an example of the different stages for brain organoids formation



editing induced a gain-of-function mutation in *KRAS* and a loss-of-function in all the other genes. Mutated organoids all showed independence from different growth factors with varying degrees of invasive behavior when transplanted, depending on the mutation(s) induced. Drost et al. also showed that sequential oncogene modifications of *APC* and *TP53* were sufficient for independence from growth factors and development of aneuploidy.

Furthermore, CRISPR/Cas9 editing in organoids has been useful for modeling diseases that could not previously be recapitulated in vitro. Sessile serrated adenomas (SSAs) are premalignant lesions of the colon, which differ both histologically and molecularly from lesions associated with mutations in the *APC* gene, even though both are able to drive colorectal cancer development [108]. Following analysis of polyps from SSA patients, the activating *BRAF* proto-oncogene with *V600E* mutation was commonly found in association with the disease [103]. By introducing the *BRAF*<sup>V600E</sup> mutation into wild-type colorectal organoids, Fessler et al. obtained organoids that grew independently from TGF- $\beta$  signaling and showed epithelial-mesenchymal transition, a phenotype associated with early oncogenesis [30].

Genetic editing in organoids can also be used in screening for efficient drug responses. Verissimo and colleagues used colorectal organoids harboring different RAS mutations to test how they affect the response to EGFR and MEK inhibitors [111]. While wild-type organoids showed sensitivity to the inhibitors, organoids with oncogenic *KRAS* mutations introduced by CRISPR/Cas9 displayed reduced sensitivity to the drugs. In the mutant organoids, the drugs induced cell-cycle arrest rather than cell death, demonstrating the potential of using CRISPR/Cas9-edited organoid libraries for large-scale screens.

However, to study the effect of multiple mutations simultaneously using a CRISPR/Cas9 knockout screen, cloning and delivery of multiple gRNAs are required, thus minimizing the efficiency of the process in a large-scale study. The development of a new tool for multiplexing gRNA expression in a concatemer vector generated through the design of specific gRNA overhangs allows one-step cloning of up to four gene knockouts simultaneously [3]. As a proof of concept, the authors induced simultaneous knockouts of genes involved in *WNT* signaling regulation and their paralogues in small intestinal organoids and demonstrated that the organoids became *WNT* independent. This method could be useful for performing screens with multiple gene targets in oncogenic or disease modeling studies.

More recently, human colon-derived organoids have been edited to model traditional serrated adenoma (TSA) [54]. This rare subtype of colonic serrated adenomas is characterized by distinct serration morphology, villiform structures, and ectopic crypt formation. Using CRISPR/Cas9 introduced by electroporation in wild-type and *TP53*-knockout human colonic

organoids, the authors knocked in a *BRAF* mutation, overexpressed the *GREM1* gene, and generated long-range gene fusions. Following transplantation, organoids expressing mutant *BRAF* and *GREM1* displayed phenotypes similar to those seen in TSA patients.

## Liver organoids

The liver contains two epithelial cell types: hepatocytes and ductal cells. Expression of *LGR5*, which marks adult stem cells in the stomach, intestine, and colon, is barely present in homeostatic, healthy liver. However, upon injury, *Lgr5*+ cells appear around the bile duct to replenish the damaged tissue [45]. Because of this proliferative capacity, *Lgr5*+ cells were also used to establish liver organoids, which could be transplanted to rescue fumarylacetonacetate hydrolase (FAH)-deficient mice from liver failure upon withdrawal of nitisinone (NTBC) [7].

In 2016, Broutier et al. published a protocol detailing methods for genetic manipulation of liver and pancreatic organoids. The established tool utilized stably integrated retroviral transduction or transiently expressed liposomal transfection coupled with CRISPR/Cas9 editing. Editing efficiency was determined by detection of a fluorescent reporter or expression of a drug selection marker [15]. However, these methods required organoid dissociation into single cells, thus lowering the editing efficiency overall. Liver organoids can also be edited using adeno-associated virus vectors [116]. Using the adapted AAV-DJ vector expressing human *HNF4 $\alpha$* , a master regulator inducing hepatocyte differentiation, the authors showed increased hepatocyte formation in liver organoids compared to wild-type controls.

## Mammary epithelial organoids

The existence of tissue stem/progenitor cells in the mammary gland is suggested by the multiple cycles of tissue remodeling during the menstrual cycle and pregnancy. The first human mammary gland organoid culture was reported by Linnemann and colleagues in 2015 [69]. Since then, there have been many refinements of mammary gland organoid culture to improve recapitulation of in vivo tissue architecture and function [49, 100].

Recently, Dekkers and colleagues showed that it is possible to use CRISPR/Cas9 editing in mammary epithelial organoids derived from human reduction mammoplasty patients in order to model the clonal evolution in breast cancer development [22]. Using mammary epithelial cells sorted from normal reduction mammoplasties, the team generated human mammary epithelial organoids. Targeted knockout of four tumor suppressor genes, *TP53*, *PTEN*, *RBI*, and *NF1*, induced long-term culturability and tumor formation upon murine transplantation. This work suggests a potential use of CRISPR/

Cas9 editing as a technique for modeling mammary epithelial-associated diseases.

## Editing in pluripotent stem cell-derived organoids

Pluripotent stem cells can give rise to cells from all three germ layers in vitro, given the appropriate culture conditions. For this reason, organoids generated from PSCs often consist of cells derived from more than one germ layer, allowing the study of interaction between various cell types and providing a model that more closely mimics endogenous organs [79, 102]. Furthermore, establishing gene-edited organoids from PSCs is relatively more straightforward than from AdSCs, as editing can be done directly in PSCs prior to organoid differentiation as discussed below (Fig. 2b). This circumvents the need to dissociate organoids for transfection of the genome-editing machinery, which may reduce the overall efficiency of organoid editing [23].

## Brain organoids

The brain is one of the most complex organs in the vertebrate body. Studies to understand the human brain had been limited by the accessibility to brain tissue and ethical constraints. However, following initial reports by the group of Yoshiki Sasai, brain research has benefited from the development of 3D in vitro models of different specific regions of the brain, including the cortex [26], pituitary gland [105], cerebellum [78], hippocampus [52], and even whole brain organoids [65]. These models provide a platform for understanding factors regulating normal brain development.

As brain organoids are solely derived from PSCs, disease modeling in brain organoids has relied heavily on human iPSCs derived from patients, with or without genetic editing of the iPSCs prior to organoid differentiation. For example, Sandhoff disease, a lysosomal storage disorder caused by a mutation in *HEXB*, leading to neurodegeneration and early childhood death, was modeled using cerebral organoids developed from patient-derived human iPSCs [2]. CRISPR/Cas9-edited correction of the loss-of-function mutation in human iPSCs produced disease-free organoids, indicating that CRISPR/Cas9 gene editing could be used for testing the importance of disease-causing mutations. A glioblastoma cancer model was also developed by introducing an activating *HRAS* oncogenic mutation into the *TP53* locus of human PSCs, knocking out the *TP53* allele while introducing the *HRAS* oncogene [82]. In addition, human iPSCs were edited to introduce the *LRRK*<sup>G2019S</sup> mutation and differentiated to form midbrain organoids that display features of Parkinson's disease [58].

One potential disadvantage of introducing genetic modifications into PSCs is that it results in the generation of organoids containing only mutant cells, thus limiting the interaction between wild-type cells and mutants that would normally exist in endogenous diseased tissues. A new method of introducing oncogenic mutations directly into neuroepithelial cells, rather than into PSCs prior to neural induction, using CRISPR/Cas9 to induce tumor suppressor knockout together with Sleeping Beauty transposons to induce oncogene expression, generated organoids that more closely mimic the in vivo tumor organization, containing both transformed and non-transformed cells in close proximity [12]. This model is valuable for tumor studies as well as for drug screening, as it provides a platform that enables study of the wild-type cells in the same system.

## Gastrointestinal tract organoids

While gastrointestinal tract organoids such as gastric, intestinal, and colorectal organoids have been successfully generated from tissue-resident stem cells [10, 51, 96], it is also possible to derive organoids of these organs from PSCs [73, 74, 79, 102]. This method provides a useful resource for performing genetic studies of human diseases. Woo and colleagues used the CRISPR/Cas9 system to generate iPSCs with a mutation in the *DKC1* gene, which encodes DYSKERIN, a protein essential in telomere maintenance [118]. Patients with dyskeratosis congenita (DC) often have a mutation in the *DKC1* gene leading to accelerated degeneration of highly-proliferative tissues such as the epidermis, the gastrointestinal tract, and the hematopoietic system [5, 29]. By differentiating the edited PSCs into intestinal organoids, the authors could show that the mutant organoids have shorter telomeres and fail to maintain budding crypts, resembling diseased phenotypes [118].

## Kidney organoids

The kidney is a highly structured organ consisting of more than 20 cell types, organized into networks of nephrons, vasculature, and interstitial compartments. The establishment of kidney organoids occurs through stepwise-directed differentiation, mimicking the in vivo kidney developmental process [77, 106]. First, 2D cultures of hPSCs are differentiated to intermediate mesodermal cells, then specifically to posterior intermediate mesoderm. Further differentiation steps lead to the establishment of metanephric mesenchyme and later kidney organoids containing nephrons with glomeruli and Bowman's capsule-like structures, as well as proximal and distal tubules connected by the loop of Henle [77, 106].

In 2015, Freedman and colleagues established a polycystic kidney disease (PKD) model by using CRISPR/Cas9 gene editing to introduce a biallelic mutation in *PKD1* or *PKD2*

[31]. The loss of function of either PKD1 or PKD2 is sufficient to induce autosomal dominant polycystic kidney disease whereby affected individuals develop large and numerous renal cysts leading to renal failure [70, 86, 119]. Differentiation of these *PKD1* or *PKD2* mutant hPSCs into kidney organoids led to formation of large renal cysts instead of the tubular nephron-like structures.

## Genetic screening in organoids

Previously, we have discussed the use of CRISPR/Cas9 as an editing tool for genetic modification in organoids. However, recent advances have pushed the limits of editing with large-scale, high-throughput CRISPR/Cas9 screening in organoids. CRISPR/Cas9 screens allow for an unbiased determination of the causal relationship between genotype and phenotype by knocking out gene expression on a genome-wide scale and studying the resulting phenotypic change [18, 38]. In brief, CRISPR/Cas9 screens require an sgRNA library which targets every gene in the genome or in a specific gene set. Multiple sgRNAs are used to target a single gene to reduce false-positives and non-targeting sgRNAs are introduced as negative controls. The sgRNA library can be introduced into the target cells together with Cas9 endonuclease in one combined lentiviral vector or as a two-vector process where sgRNAs and Cas9 are present on separate plasmids. The screen can be performed as an array where each cell culture well is transduced with known sgRNAs from the library. In this way, the resulting phenotype can be immediately associated with a particular sgRNA without requiring sequencing. This method is especially useful for studying phenotype at single-cell level. However, this method is impractical for large-scale screening because of low-efficiency and high cost [1]. Alternatively, CRISPR/Cas9 screens can be performed in a pooled fashion where cells are transduced with bulk sgRNA library at a low multiplicity of infection (MOI) to ensure that cells are not infected by multiple sgRNAs. Infected cells are then selected and put through positive or negative selection for the phenotype of interest. Genome sequencing of selected cells is then performed to identify the sgRNAs of interest [93].

While genome-wide CRISPR/Cas9 screens are widely performed on both human and mouse immortalized cells in two-dimensional cultures [18, 38, 94, 99, 114, 115], technical limitations had limited the ability to perform CRISPR/Cas9 screens in three-dimensional organoids which would provide a more accurate model of the *in vivo* response. Due to the size of the sgRNA library and inherent noise, large number of cells would be required to have saturated coverage of the targeting sgRNA library in pooled CRISPR/Cas9 screens. The earliest screen performed in organoids targeted a small library of all nine RASGAP genes which function as negative regulators of

RAS signaling to determine the relation between RASGAP genes and EGFR-targeted therapy resistance in colorectal cancer [85]. In this study, the authors used electroporation to transfect patient-derived tumor organoids individually with a plasmid containing sgRNAs targeting each of the RASGAP genes and Cas9 endonuclease. Sequencing and mRNA expression levels were used to confirm the introduction of mutation and RASGAP gene knockouts. Using an unbiased CRISPR/Cas9 editing approach with a small-scale target library, Post et al. were able to determine NF1 as the only RASGAP gene which could enhance EGFR resistance growth upon its depletion [85]. In a later study, Planas-Paz et al. [84] performed a screen on biliary epithelial cells-like organoids (BEC-organoids) to determine essential signaling pathway in ductular reaction in which BECs function as facultative liver stem cells in response to injury. The authors utilized a DNA-barcoded lentiviral sgRNA library targeting 192 genes known to be involved in liver regeneration. DNA-barcoding accounts for BEC-organoid heterogeneous growth which could compromise sgRNA representation after selection. Further optimization was also required to determine the number of cells per sgRNA required to compensate for loss of BEC-organoids during passaging and splitting. The authors identified and validated YAP and mTORC1 as important signaling required for ductular reaction [84].

Despite these applications, CRISPR/Cas9 screens were still limited to a selective gene set when performed in organoids as contrast to genome-scale screening in two-dimensional cultures and in order to have a fully unbiased approach, performing a whole genome screening technique in organoids would be most ideal. In March 2020, the first genome-scale CRISPR screening in human intestinal organoid was performed to identify genes inducing resistance to TGF- $\beta$  signaling [91]. Initial screenings were done by transducing single organoid cell suspension with a library of tumor suppressor genes. The authors found that while organoids could be used to in CRISPR screens, there were issues in limited cell number and heterogenous growth stochastically biasing certain sgRNAs. In order to be able to perform genome-wide screening, Ringel et al. again transduced single organoid cell suspension with the sgRNA library but engineered an approach to analyze sgRNA representation in each single organoid through sequencing as opposed to collecting all surviving organoids for bulk sequencing. This method allows the authors to account for heterogenous growth as organoids would grow clonally from single cells. Using this method, the authors could identify SWI/SNF complex components as regulators of TGF- $\beta$  activity [91]. In an alternative approach, Michels et al. utilized CRISPR-UMI and a pre-screening method with HepG2 cancer cell lines to account for heterogenous organoid growth and differences in sgRNA functionality within clonal organoids [75]. The authors showed through a preliminary



screen with all tumor suppressor genes that pooled screening in organoids is prone to false positives as organoids are notoriously heterogeneous in growth therefore high sgRNA abundance may not be due to a biological effect but due to random outgrowth of any arbitrary organoid. In order to account of this, the authors made use of CRISPR-UMI method where each sgRNA is paired to barcode of ten random nucleotides allowing identification of single cell-derived clones [76]. Furthermore, Michels et al. also showed that sgRNA phenotypic strength and penetrance are more variable in organoids despite prediction from existing design algorithms and functionality in transformed HepG2 cancer cell lines. To improve this, the authors suggest that gRNA-reporter prescreening in cancer cell models could be performed to reduce library size and gain increased coverage. With these modifications, the CRISPR screen was performed with pan-cancer tumor suppressor gene library in APC<sup>-/-</sup>; KRas<sup>G12D</sup> pre-oncogenic organoids to study clonal advantage in complex microenvironment upon organoid xenotransplantation. The authors could identify TGFBR2 as an essential hit in inducing clonal advantage from the large-scale screen [75].

While CRISPR/Cas9 screening in organoids presents several limitations when compared to cell line screening due to difficulties in manual handling of 3D organoids at a large scale, based on these findings, appropriate scale CRISPR/Cas9 screen is shown to be feasible with organoid models. Initial issues with small cell number for sufficient sgRNA library coverage and heterogeneous organoid outgrowth can be solved by single organoid sequencing or transducing large cell population with CRISPR/UMI library. Furthermore, improving sgRNA design for organoids could increase phenotypic induction and penetrance thus enhancing the CRISPR/Cas9 organoid screening platform to eventually allow for targeting patient-specific mutations or vulnerabilities.

## Discussion

In this chapter, we have given examples of the possible applications of different genetic engineering techniques in different types of organoids. It is perhaps helpful to now provide a guideline for the considerations that need to be taken into account when deciding which delivery system and which genetic engineering tools to utilize. Each consideration should be dependent on the type of organoid system to be used, as well as the type and purpose of editing. As a proof of principle, we will discuss two examples to showcase the thought process involved in selecting the necessary tools.

If the aim is to utilize brain organoids to model a certain monogenic disease, one has to consider when the mutation should be introduced and how. As brain organoids are grown from PSCs, it is possible to genetically edit PSCs prior to

differentiation into organoids. This method is simpler and more efficient; however, if the desired mutation prevents the progress of the necessary steps involved in the organoid differentiation, then one has to carefully consider the alternative of editing in organoids or utilizing an inducible editing system instead. Secondly, how the disease will be modeled genetically has to be considered. Is constant expression of the mutant sequence necessary? Is a knockdown of gene expression sufficient to generate the disease phenotype? Is the disease caused by a large insertion or deletion mutation or by a point mutation? If only a knockdown of gene expression is sufficient, it would be more efficient to utilize the RNAi system for editing coupled with non-integrating viral transfection. If permanent large insertion is required, using transposons as a method of editing may be effective. However, if a specific single-base pair sequence substitution is the cause of the disease, it would be more precise to utilize the CRISPR/Cas9 system with HDR or base and prime editing for permanent DNA modification.

In another example, if the aim is to use intestinal organoids to conduct a screen for mutations that induce resistance to a specific drug, then different criteria need to be considered. Transposon editing to introduce mutations is generally difficult to perform on the large scale required for this type of screen, in which multiple genes have to be targeted at once. It is therefore more efficient to use the RNAi or CRISPR/Cas9 system. RNAi screens are often conducted with shRNAs rather than siRNAs, as expression of siRNAs is transient and does not leave a molecular signature in the cells they were introduced into, thus making it difficult to analyze the specific effects of each mutation. Furthermore, siRNA libraries are challenging to clone since targeting RNAs need to be arrayed and individually assessed prior to screening. On the other hand, utilizing retro-/lentivirus encoding shRNAs circumvents all these challenges and provides the ability to perform pooled screenings. All shRNAs can be introduced into the same cell culture or organoid dissociates, followed by isolation of single cells for clonal organoid expansion. At the end of the experiment, hits from the screen can be identified by PCR amplification of the shRNA sequence in the genome. However, the main problem with the RNAi system is that it introduces a knockdown rather than a knockout. Knockdowns can lead to hypomorphic changes and if there is insufficient knockdown of the expression, the shRNAs would not be detected as hits in the screen. Furthermore, shRNAs are prone to off-target effects and require consistent expression throughout the experiment for effects to be detected. A more convenient method for use in screens is the CRISPR/Cas9 system. CRISPR/Cas9 editing is precise and can be barcoded, providing an easily identifiable sequence that can be detected during the screen analysis. CRISPR/Cas9 editing is also permanent and still useful for screening in diploid cells.

## Concluding remarks

In this chapter, we have described the various techniques available for genetic manipulation of organoids to use for different purposes. Although it might be tempting to utilize the newest and most challenging techniques to demonstrate the complexity of a study, it is important to consider the requirements, depending on the project. Choosing the techniques and tools with which you are experienced and knowledgeable, and which best support your model and experimental questions, is the most effective way to achieve the desired outcome.

**Authors' contributions** I.T. drafted the manuscript; A.B.-R. prepared figures; B.-K.K. edited and revised the manuscript.

**Funding** Open Access funding provided by Research Institute of Molecular Pathology (IMP) / Institute of Molecular Biotechnology (IMBA)/ Gregor Mendel Institute of Molecular Plant Biology (GMI). I.T. is supported by SCORPION Doc.Funds. (DOC 72). B.-K.K.'s laboratory is supported by the Austrian Academy of Sciences, Human Frontier Science Program, and Interpark Bio-Convergence Center Grant Program.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethics approval** Not applicable.

**Consent to participate** Not applicable.

**Consent for publication** Not applicable.

**Code availability** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Agrotis, A. and Ketteler, R. (2015) 'A new age in functional genomics using CRISPR/Cas9 in arrayed library screening'. *Frontiers in Genetics*. Frontiers Media S.A. <https://doi.org/10.3389/fgene.2015.00300>
- Allende ML, Cook EK, Larman BC, Nugent A, Brady JM, Golebiowski D, Sena-Esteves M, Tiffit CJ, Proia RL (2018) Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation. *Journal of Lipid Research American Society for Biochemistry and Molecular Biology Inc* 59(3):550–563
- Andersson-Rolf A, Merenda A, Mustata RC, Li T, Dietmann S, Koo BK (2016) Simultaneous paralogue knockout using a CRISPR-concatemer in mouse small intestinal organoids. *Developmental Biology Academic Press Inc* 420(2):271–277
- Antonica F, Kasprzyk DF, Opitz R, Iacovino M, Liao XH, Dumitrescu AM, Refetoff S, Peremans K, Manto M, Kyba M, Costagliola S (2012) Generation of functional thyroid from embryonic stem cells. *Nature Nat Publ Group* 491(7422):66–71
- Armanios M, Blackburn EH (2012) 'The telomere syndromes.' *Nat Rev Genet* 693–704. <https://doi.org/10.1038/nrg3246>
- Artigiani B, Hendriks D, Beumer J, Kok R, Zheng X, Joore I, Chuva de Sousa Lopes S, van Zon J, Tans S, Clevers H (2020) Fast and efficient generation of knock-in human organoids using homology-independent CRISPR–Cas9 precision genome editing. *Nature Cell Biology*. *Nature Research* 22(3):321–331
- Azuma H, Paulk N, Ranade A, Dorrell C, al-Dhalimy M, Ellis E, Strom S, Kay MA, Finegold M, Grompe M (2007) Robust expansion of human hepatocytes in Fah<sup>-/-</sup>Rag2<sup>-/-</sup>Il2rg<sup>-/-</sup> mice. *Nat Biotechnol* 25(8):903–910
- Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, Stange DE, Begthel H, van den Born M, Danenberg E, van den Brink S, Korving J, Abo A, Peters PJ, Wright N, Poulsom R, Clevers H (2010) Lgr5+ve stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. *Cell Stem Cell*. Elsevier Ltd 6(1):25–36
- Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P (2007) CRISPR provides acquired resistance against viruses in prokaryotes. *Science* 315(5819):1709–1712
- Bartfeld S et al (2015) In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection. *Gastroenterology* 148(1):126–136.e6
- Batchelder CA et al (2015) Three dimensional culture of human renal cell carcinoma organoids. *PLOS ONE*. Edited by F. Zhao 10(8):e0136758
- Bian S, Repic M, Guo Z, Kavirayani A, Burkard T, Bagley JA, Krauditsch C, Knoblich JA (2018) Genetically engineered cerebral organoids model brain tumor formation. *Nature Methods Nat Publ Group* 15(8):631–639
- Bollen, Y. et al. (2018) 'How to create state-of-the-art genetic model systems: strategies for optimal CRISPR-mediated genome editing'. *Nucleic Acids Research*. Oxford University Press, pp. 6435–6454. <https://doi.org/10.1093/nar/gky571>
- Boretto M, Cox B, Noben M, Hendriks N, Fassbender A, Roose H, Amant F, Timmerman D, Tomassetti C, Vanhie A, Meuleman C, Ferrante M, Vankelecom H (2017) Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. *Development (Cambridge) Company of Biologists Ltd* 144(10):1775–1786
- Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK, Huch M (2016) Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. *Nature Protocols Nat Publ Group* 11(9):1724–1743
- Cho SW, Kim S, Kim JM, Kim JS (2013) Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. *Nature Biotechnology Nat Publ Group* 31(3):230–232
- Clevers H (2016) Modeling development and disease with organoids. *Cell*. *Cell Press* 165(7):1586–1597

18. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR/Cas systems. *Science*. American Association for the Advancement of Science 339(6121):819–823
19. Cornu, T. I., Mussolino, C. and Cathomen, T. (2017) ‘Refining strategies to translate genome editing to the clinic’. *Nature Medicine*. Nature Publishing Group, pp. 415–423. <https://doi.org/10.1038/nm.4313>
20. Dang J, Tiwari SK, Lichinchi G, Qin Y, Patil VS, Eroshkin AM, Rana TM (2016) Zika virus depletes neural progenitors in human cerebral organoids through activation of the innate immune receptor TLR3. *Cell Stem Cell Elsevier Inc.* 19(2):258–265
21. De Van Lidth Jeude, J. F. et al. (2015) ‘A protocol for lentiviral transduction and downstream analysis of intestinal organoids’. *Journal of Visualized Experiments*. Journal of Visualized Experiments, 2015(98). <https://doi.org/10.3791/52531>
22. Dekkers JF, Whittle JR, Vaillant F, Chen HR, Dawson C, Liu K, Geurts MH, Herold MJ, Clevers H, Lindeman GJ, Visvader JE (2019) Modeling breast cancer using CRISPR-Cas9-mediated engineering of human breast organoids. *JNCI: Journal of the National Cancer Institute* 112:540–544
23. Driehuis, E. and Clevers, H. (2017) ‘CRISPR/Cas 9 genome editing and its applications in organoids’. *American Journal of Physiology - Gastrointestinal and Liver Physiology*, pp. G257–G265. <https://doi.org/10.1152/ajpgi.00410.2016>
24. Drost J, van Jaarsveld RH, Ponsioen B, Zimmerlin C, van Boxtel R, Buijs A, Sachs N, Overmeer RM, Offerhaus GJ, Begthel H, Korving J, van de Wetering M, Schwank G, Logtenberg M, Cuppen E, Snippert HJ, Medema JP, Kops GJPL, Clevers H (2015) Sequential cancer mutations in cultured human intestinal stem cells. *Nature* Nature Publishing Group 521(7550):43–47
25. Dye BR, Hill DR, Ferguson MAH, Tsai YH, Nagy MS, Dyal R, Wells JM, Mayhew CN, Nattiv R, Klein OD, White ES, Deutsch GH, Spence JR (2015) In vitro generation of human pluripotent stem cell derived lung organoids. *eLife eLife Sciences Publications Ltd* 2015(4):1–25
26. Eiraku M, Watanabe K, Matsuo-Takasaki M, Kawada M, Yonemura S, Matsumura M, Wataya T, Nishiyama A, Muguruma K, Sasai Y (2008) Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. *Cell Stem Cell Elsevier Inc.* 3(5):519–532
27. Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S, Sekiguchi K, Adachi T, Sasai Y (2011) Self-organizing optic-cup morphogenesis in three-dimensional culture. *Nature*. Nature Publishing Group 472(7341):51–58
28. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature*. Nature Publishing Group 411(6836):494–498
29. Fernández García, M. S. and Teruya-Feldstein, J. (2014) ‘The diagnosis and treatment of dyskeratosis congenita: a review’. *Journal of Blood Medicine*. Dove Medical Press Ltd, pp. 157–167. <https://doi.org/10.2147/JBM.S47437>
30. Fessler, E. et al. (2016) ‘TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype’. *EMBO Molecular Medicine*. EMBO, 8(7), pp. 745–760. <https://doi.org/10.15252/emmm.201606184>
31. Freedman, B. S. et al. (2015) ‘Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids’. *Nature Communications*. Nature Publishing Group, 6. <https://doi.org/10.1038/ncomms9715>
32. Fujii M, Matano M, Nanki K, Sato T (2015) Efficient genetic engineering of human intestinal organoids using electroporation. *Nat Protoc* 10(10):1474–1485
33. Fujii, M., Clevers, H. and Sato, T. (2019) ‘Modeling human digestive diseases with CRISPR-Cas9-modified organoids’. *Gastroenterology*. W.B. Saunders, pp. 562–576. <https://doi.org/10.1053/j.gastro.2018.11.048>
34. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, Dowling C, Wanjala JN, Undvall EA, Arora VK, Wongvipat J, Kossai M, Ramazanoglu S, Barboza LP, di W, Cao Z, Zhang QF, Sirota I, Ran L, MacDonald TY, Beltran H, Mosquera JM, Touijer KA, Scardino PT, Laudone VP, Curtis KR, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Solomon SB, Eastham JA, Chi P, Carver B, Rubin MA, Scher HI, Clevers H, Sawyers CL, Chen Y (2014) Organoid cultures derived from patients with advanced prostate cancer. *Cell* 159(1):176–187
35. Gasiunas G, Barrangou R, Horvath P, Siksnyš V (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. *Proc Natl Acad Sci U S A* 109(39):E2579–E2586
36. Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR (2017) Programmable base editing of T to G C in genomic DNA without DNA cleavage. *Nature*. Nature Publishing Group 551(7681):464–471
37. Geurts, M. H. et al. (2020) ‘CRISPR-based adenine editors correct nonsense mutations in a cystic fibrosis organoid biobank’. *Cell Stem Cell*. Cell Press, 26(4), pp. 503–510.e7. <https://doi.org/10.1016/j.stem.2020.01.019>
38. Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, Qi LS, Kampmann M, Weissman JS (2014) Genome-scale CRISPR-mediated control of gene repression and activation. *Cell*. Cell Press 159(3):647–661
39. Hammond, S. M., Caudy, A. A. and Hannon, G. J. (2001) ‘Post-transcriptional gene silencing by double-stranded RNA’. *Nature Reviews Genetics*. Nature Publishing Group, pp. 110–119. <https://doi.org/10.1038/35052556>
40. Hess, G. T. et al. (2017) ‘Methods and applications of CRISPR-mediated base editing in eukaryotic genomes’. *Molecular Cell*. Cell Press, pp. 26–43. <https://doi.org/10.1016/j.molcel.2017.09.029>
41. Hu, H. et al. (2018a) ‘Long-term expansion of functional mouse and human hepatocytes as 3D organoids’. *Cell*. Cell Press, 175(6), pp. 1591–1606.e19. <https://doi.org/10.1016/j.cell.2018.11.013>
42. Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, Zeina CM, Gao X, Rees HA, Lin Z, Liu DR (2018b) Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. *Nature*. Nature Publishing Group 556(7699):57–63
43. Huch M, Koo BK (2015) Modeling mouse and human development using organoid cultures’. *Development (Cambridge)*. Company of Biologists Ltd 142:3113–3125
44. Huch M, Bonfanti P, Boj SF, Sato T, Loomans CJM, van de Wetering M, Sojoodi M, Li VSW, Schuijers J, Gracanin A, Ringnalda F, Begthel H, Hamer K, Mulder J, van Es JH, de Koning E, Vries RGJ, Heimberg H, Clevers H (2013a) Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. *EMBO Journal*. John Wiley & Sons, Ltd 32(20):2708–2721
45. Huch M, Dorrell C, Boj SF, van Es JH, Li VSW, van de Wetering M, Sato T, Hamer K, Sasaki N, Finegold MJ, Haft A, Vries RG, Grompe M, Clevers H (2013b) In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. *Nature*. Nature Publishing Group 494(7436):247–250
46. Hudecek M, Izsvák Z, Johnen S, Renner M, Thumann G, Ivics Z (2017) Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. *Crit Rev Biochem Mol Biol* 52(4):355–380
47. Hustedt, N. and Durocher, D. (2017) ‘The control of DNA repair by the cell cycle’. *Nature Cell Biology*. Nature Publishing Group, pp. 1–9. <https://doi.org/10.1038/ncb3452>



48. Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, Kommineni S, Chen J, Sondey M, Ye C, Randhawa R, Kulkarni T, Yang Z, McAllister G, Russ C, Reece-Hoyes J, Forrester W, Hoffman GR, Dolmetsch R, Kaykas A (2018) P53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. *Nature Medicine Nat Publ Group* 24(7):939–946
49. Jamieson PR, Dekkers JF, Rios AC, Fu NY, Lindeman GJ, Visvader JE (2017) Derivation of a robust mouse mammary organoid system for studying tissue dynamics. *Company of Biologists Ltd, Development* 144(6):1065–1071
50. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science. American Association for the Advancement of Science* 337(6096):816–821
51. Jung P, Sato T, Merlos-Suárez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E (2011) Isolation and in vitro expansion of human colonic stem cells. *Nat Med* 17(10):1225–1227
52. Kadoshima T, Sakaguchi H, Nakano T, Soen M, Ando S, Eiraku M, Sasai Y (2013) Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. *Proc Natl Acad Sci* 110(50):20284–20289
53. Karthaus WR, Iaquina PJ, Drost J, Gracanin A, van Boxtel R, Wongvipat J, Dowling CM, Gao D, Begthel H, Sachs N, Vries RGJ, Cuppen E, Chen Y, Sawyers CL, Clevers HC (2014) Identification of multipotent luminal progenitor cells in human prostate organoid cultures. *Cell Elsevier Inc* 159(1):163–175
54. Kawasaki K, Fujii M, Sugimoto S, Ishikawa K, Matano M, Ohta Y, Toshimitsu K, Takahashi S, Hosoe N, Sekine S, Kanai T, Sato T (2019) Chromosome engineering of human colon-derived organoids to develop a model of traditional serrated adenoma. *Gastroenterology Elsevier BV* doi 158:638–651.e8
55. Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, Berger H, Mollenkopf HJ, Mangler M, Sehoul J, Fotopoulou C, Meyer TF (2015) The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. *Nature Communications. Nat Publ Group* 6(May):1–11
56. Khan, S. H. (2019) ‘Genome-editing technologies: concept, pros, and cons of various genome-editing techniques and bioethical concerns for clinical application’. *Molecular Therapy - Nucleic Acids. Cell Press*, pp. 326–334. <https://doi.org/10.1016/j.omtn.2019.02.027>
57. Kim, J. S. (2016) ‘Genome editing comes of age’. *Nature Protocols. Nature Publishing Group*, pp. 1573–1578. <https://doi.org/10.1038/nprot.2016.104>
58. Kim H, Park HJ, Choi H, Chang Y, Park H, Shin J, Kim J, Lengner CJ, Lee YK, Kim J (2019) Modeling G2019S-LRRK2 sporadic Parkinson’s disease in 3D midbrain organoids. *Stem Cell Reports Cell Press* 12(3):518–531
59. Koehler KR, Mikosz AM, Molosh AI, Patel D, Hashino E (2013) Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture. *Nature. Nature Publishing Group* 500(7461):217–221
60. Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature. Nature Publishing Group* 533(7603):420–424
61. Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJR, Maurice MM, Clevers H (2012a) Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. *Nature* 488(7413):665–669
62. Koo BK, Stange DE, Sato T, Karthaus W, Farin HF, Huch M, van Es JH, Clevers H (2012b) Controlled gene expression in primary Lgr5 organoid cultures. *Nat Methods* 9(1):81–83
63. Kurmann AA, Serra M, Hawkins F, Rankin SA, Mori M, Astapova I, Ullas S, Lin S, Bilodeau M, Rossant J, Jean JC, Ikonomou L, Deterding RR, Shannon JM, Zorn AM, Hollenberg AN, Kotton DN (2015) Regeneration of thyroid function by transplantation of differentiated pluripotent stem cells. *Cell Stem Cell Elsevier Inc* 17(5):527–542
64. Lancaster MA, Knoblich JA (2014) Organogenesis in a dish: modeling development and disease using organoid technologies. *Science* 345(6194):1247125
65. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurler ME, Homfray T, Penninger JM, Jackson AP, Knoblich JA (2013) Cerebral organoids model human brain development and microcephaly. *Nature. Nature Publishing Group* 501(7467):373–379
66. Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. *Nat Methods* 4(4):359–365
67. Lee JH, Bhang DH, Beede A, Huang TL, Stripp BR, Bloch KD, Wagers AJ, Tseng YH, Ryeom S, Kim CF (2014) Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis. *Cell Elsevier* 156(3):440–455
68. Li X, Nadauld L, Ootani A, Corney DC, Pai RK, Gevaert O, Cantrell MA, Rack PG, Neal JT, Chan CWM, Yeung T, Gong X, Yuan J, Wilhelm J, Robine S, Attardi LD, Plevritis SK, Hung KE, Chen CZ, Ji HP, Kuo CJ (2014) Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. *Nature Medicine Nat Publ Group* 20(7):769–777
69. Linnemann JR, Miura H, Meixner LK, Irmeler M, Kloos UJ, Hirschi B, Bartsch HS, Sass S, Beckers J, Theis FJ, Gabka C, Sotlar K, Scheel CH (2015) Quantification of regenerative potential in primary human mammary epithelial cells. *Development* 142(18):3239–3251
70. Lu, W. et al. (1999) ‘Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes [4]’. *Nature Genetics*, pp. 160–161. <https://doi.org/10.1038/5944>
71. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. *Science. American Association for the Advancement of Science* 339(6121):823–826
72. Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, Kanai T, Sato T (2015) Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nature Medicine Nat Publ Group* 21(3):256–262
73. McCracken KW, Catá EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE, Tsai YH, Mayhew CN, Spence JR, Zavros Y, Wells JM (2014) Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. *Nature. Nature Publishing Group* 516(7531):400–404
74. McCracken KW, Aihara E, Martin B, Crawford CM, Broda T, Treguier J, Zhang X, Shannon JM, Montrose MH, Wells JM (2017) Wnt/ $\beta$ -catenin promotes gastric fundus specification in mice and humans. *Nature. Nature Publishing Group* 541(7636):182–187
75. Michels, B. E. et al. (2020) ‘Pooled in vitro and in vivo CRISPR-Cas9 screening identifies tumor suppressors in human colon organoids’. *Cell Stem Cell. Cell Press*, 26(5), pp. 782–792.e7. <https://doi.org/10.1016/j.stem.2020.04.003>
76. Michlits G, Hubmann M, Wu SH, Vainorius G, Budusan E, Zhuk S, Burkard TR, Novatchkova M, Aichinger M, Lu Y, Reece-Hoyes J, Nitsch R, Schramek D, Hoepfner D, Elling U (2017) CRISPR-UMI: single-cell lineage tracing of pooled CRISPR-Cas9 screens. *Nature Methods. Nat Publ Group* 14(12):1191–1197
77. Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV (2015) Nephron organoids derived from human



- pluripotent stem cells model kidney development and injury'. *Nature Biotechnology*. Nat Publ Group 33(11):1193–1200
78. Muguruma K, Nishiyama A, Kawakami H, Hashimoto K, Sasai Y (2015) Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. *Cell Rep* 10(4):537–550
  79. Múnera, J. O. et al. (2017) 'Differentiation of human pluripotent stem cells into colonic organoids via transient activation of BMP signaling'. *Cell Stem Cell*. Cell Press, 21(1), pp. 51–64.e6. <https://doi.org/10.1016/j.stem.2017.05.020>
  80. Nadauld, L. D. et al. (2014) 'Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer'. *Genome biology*, 15(8), p. 428. <https://doi.org/10.1186/s13059-014-0428-9>
  81. Nanduri LSY, Baanstra M, Faber H, Rocchi C, Zwart E, de Haan G, van Os R, Coppes RP (2014) Purification and ex vivo expansion of fully functional salivary gland stem cells. *Stem Cell Reports The Authors* 3(6):957–964
  82. Ogawa, J. et al. (2018) 'Glioblastoma model using human cerebral organoids'. *Cell Reports*. Elsevier B.V., 23(4), pp. 1220–1229. <https://doi.org/10.1016/j.celrep.2018.03.105>
  83. Peng, W. C. et al. (2018) 'Inflammatory cytokine TNF $\alpha$  promotes the long-term expansion of primary hepatocytes in 3D culture'. *Cell*. Cell Press, 175(6), pp. 1607–1619.e15. <https://doi.org/10.1016/j.cell.2018.11.012>
  84. Planas-Paz, L. et al. (2019) 'YAP, but not RSPO-LGR4/5, signaling in biliary epithelial cells promotes a ductular reaction in response to liver injury'. *Cell Stem Cell*. Cell Press, 25(1), pp. 39–53.e10. <https://doi.org/10.1016/j.stem.2019.04.005>
  85. Post, J. B. et al. (2019) 'CRISPR-induced RASGAP deficiencies in colorectal cancer organoids reveal that only loss of NF1 promotes resistance to EGFR inhibition'. *Oncotarget*. Impact Journals LLC, 10(14), pp. 1440–1457. <https://doi.org/10.18632/oncotarget.26677>
  86. Qian F, Watnick TJ, Onuchic LF, Germino GG (1996) The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. *Cell*. Cell Press 87(6):979–987
  87. Qian X, Nguyen HN, Song MM, Hadiono C, Ogden SC, Hammack C, Yao B, Hamersky GR, Jacob F, Zhong C, Yoon KJ, Jeang W, Lin L, Li Y, Thakor J, Berg DA, Zhang C, Kang E, Chickering M, Nauen D, Ho CY, Wen Z, Christian KM, Shi PY, Maher BJ, Wu H, Jin P, Tang H, Song H, Ming GL (2016) Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. *Cell*. Elsevier Inc. 165(5):1238–1254
  88. Qu Y, Han B, Gao B, Bose S, Gong Y, Wawrowsky K, Giuliano AE, Sareen D, Cui X (2017) Stem cell reports differentiation of human induced pluripotent stem cells to mammary-like organoids. *Stem Cell Reports*. Elsevier Company. 8(2):205–215
  89. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F (2013) Double nicking by RNA-guided CRISPR cas9 for enhanced genome editing specificity. *Cell* 154(6):1380–1389
  90. Ren W, Lewandowski BC, Watson J, Aihara E, Iwatsuki K, Bachmanov AA, Margolskee RF, Jiang P (2014) Single Lgr5- or Lgr6-expressing taste stem/progenitor cells generate taste bud cells ex vivo. *Proc Natl Acad Sci U S A* 111(46):16401–16406
  91. Ringel, T. et al. (2020) 'Genome-scale CRISPR screening in human intestinal organoids identifies drivers of TGF- $\beta$  resistance'. *Cell Stem Cell*. Cell Press, 26(3), pp. 431–440.e8. <https://doi.org/10.1016/j.stem.2020.02.007>
  92. Roe T, Reynolds TC, Yu G, Brown PO (1993) Integration of murine leukemia virus DNA depends on mitosis. *The EMBO Journal Wiley* 12(5):2099–2108
  93. Sanjana NE (2017) Genome-scale CRISPR pooled screens. *Analytical Biochemistry Academic Press Inc* 532:95–99
  94. Sanjana, N. E., Shalem, O. and Zhang, F. (2014) 'Improved vectors and genome-wide libraries for CRISPR screening'. *Nature Methods*. Nature Publishing Group, pp. 783–784. <https://doi.org/10.1038/nmeth.3047>
  95. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature Nat Publ Group* 459(7244):262–265
  96. Sato T, Stange DE, Ferrante M, Vries RGJ, van Es JH, van den Brink S, van Houdt WJ, Pronk A, van Gorp J, Siersema PD, Clevers H (2011) Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* 141(5):1762–1772
  97. Schwank, G., Andersson-Rolf, A., et al. (2013a) 'Generation of BAC transgenic epithelial organoids', *PLoS ONE*. Edited by D. Unutmaz, 8(10), p. e76871. <https://doi.org/10.1371/journal.pone.0076871>
  98. Schwank G, Koo BK, Sasselli V, Dekkers JF, Heo I, Demircan T, Sasaki N, Boymans S, Cuppen E, van der Ent CK, Nieuwenhuis EES, Beekman JM, Clevers H (2013b) Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell Stem Cell* 13(6):653–658
  99. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science American Association for the Advancement of Science* 343(6166):84–87
  100. Sokol ES, Miller DH, Breggia A, Spencer KC, Arendt LM, Gupta PB (2016) Growth of human breast tissues from patient cells in 3D hydrogel scaffolds. *Breast Cancer Research BioMed Central Ltd* 18(1):1–13
  101. Somia N, Verma IM (2000) Gene therapy: trials and tribulations. *Nature Reviews Genetics European Association for Cardio-Thoracic Surgery* 1:91–99
  102. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM (2011) Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. *Nature*. Nature Publishing Group 470(7332):105–110
  103. Spring KJ, Zhao ZZ, Karamatic R, Walsh MD, Whitehall VLJ, Pike T, Simms LA, Young J, James M, Montgomery GW, Appleyard M, Hewett D, Togashi K, Jass JR, Leggett BA (2006) High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. *Gastroenterology*. W.B Saunders 131(5):1400–1407
  104. Stange DE, Koo BK, Huch M, Sibbel G, Basak O, Lyubimova A, Kujala P, Bartfeld S, Koster J, Geahlen JH, Peters PJ, van Es JH, van de Wetering M, Mills JC, Clevers H (2013) Differentiated Troy+chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. *Cell*. Elsevier Inc. 155(2):357–368
  105. Suga H, Kadoshima T, Minaguchi M, Ohgushi M, Soen M, Nakano T, Takata N, Wataya T, Muguruma K, Miyoshi H, Yonemura S, Oiso Y, Sasai Y (2011) Self-formation of functional adenohypophysis in three-dimensional culture. *Nature Nat Publ Group* 480(7375):57–62
  106. Takasato M, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, Parton RG, Wolvetang EJ, Roost MS, Chuva de Sousa Lopes SM, Little MH (2015) Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. *Nature Nat Publ Group* 526(7574):564–568
  107. Takebe T, Zhang RR, Koike H, Kimura M, Yoshizawa E, Enomura M, Koike N, Sekine K, Taniguchi H (2014) Generation of a vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature Protocols Nat Publ Group* 9(2):396–409
  108. Torlakovic EE, Gomez JD, Driman DK, Parfitt JR, Wang C, Benerjee T, Snover DC (2008) Sessile serrated adenoma (SSA)

- vs. traditional serrated adenoma (TSA). *Am J Surg Pathol* 32(1): 21–29
109. Turco MY, Gardner L, Hughes J, Cindrova-Davies T, Gomez MJ, Farrell L, Hollinshead M, Marsh SGE, Brosens JJ, Critchley HO, Simons BD, Hemberger M, Koo BK, Moffett A, Burton GJ (2017) Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium. *Nature Cell Biology Nat Publ Group* 19(5):568–577
110. Van De Wetering M et al (2015) Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell* 161(4):933–945
111. Verissimo, C. S. et al. (2016) ‘Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening’. *eLife*. eLife Sciences Publications Ltd, 5(NOVEMBER2016). <https://doi.org/10.7554/eLife.18489>
112. Villiger L, Grisch-Chan HM, Lindsay H, Ringnalda F, Pogliano CB, Allegri G, Fingerhut R, Häberle J, Matos J, Robinson MD, Thöny B, Schwank G (2018) Treatment of a metabolic liver disease by in vivo genome base editing in adult mice’. *Nature Medicine*. Nat Publ Group 24(10):1519–1525
113. Walton RT, Christie KA, Whittaker MN, Kleinstiver BP (2020) Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. *Science*. American Association for the Advancement of Science 368(6488):290–296
114. Wang, N. et al. (2014a) ‘Adenovirus-mediated efficient gene transfer into cultured three-dimensional organoids’. *PLoS ONE*. Edited by I. Ulasov, 9(4), p. e93608. <https://doi.org/10.1371/journal.pone.0093608>
115. Wang T, Wei JJ, Sabatini DM, Lander ES (2014b) Genetic screens in human cells using the CRISPR-Cas9 system. *Science American Association for the Advancement of Science* 343(6166):80–84
116. Wei J, Ran G, Wang X, Jiang N, Liang J, Lin X, Ling C, Zhao B (2019) Gene manipulation in liver ductal organoids by optimized recombinant adeno-associated virus vectors. *Journal of Biological Chemistry American Society for Biochemistry and Molecular Biology Inc*. 294(38):14096–14104
117. Wilson HV (1907) A new method by which sponges may be artificially reared. *Science* 25:912–915
118. Woo DH, Chen Q, Yang TLB, Glineburg MR, Hoge C, Leu NA, Johnson FB, Lengner CJ (2016) Enhancing a Wnt-telomere feedback loop restores intestinal stem cell function in a human organotypic model of dyskeratosis congenita. *Cell Stem Cell* 19(3):397–405
119. Wu G, D’Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, le TC, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S (1998) Somatic inactivation of Pkd2 results in polycystic kidney disease. *Cell* 93(2):177–188
120. Yin H, Kauffman KJ, Anderson DG (2017) Delivery technologies for genome editing. *Nature Reviews Drug Discovery* 16:387–399
121. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell Cell Press* 163(3):759–771

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.